BioNTech has recently undergone several key movements and announcements. The company's chief strategy officer,
Ryan Richardson, is exiting, and BioNTech's LP.8.1-adapted
COVID-19 vaccine with Pfizer received a positive opinion from the
European Medicines Agency (EMA). The agreement for
Bristol Myers to partner with BioNTech on an experimental
cancer drug has been set and valued at about $11.1 billion.
Pfizer and BioNTech also witnessed a positive CHMP opinion for COVID-19 vaccine marketing authorization. BioNTech plans to acquire
CureVac in an all-stock deal, valued around $1.25 billion, and this acquisition will significantly boost its
oncology pipeline. Consequentially, the company had to end the development of its CAR-T drug for testicular cancer, resulting in a layoff of 63 personnel in Maryland. However, BioNTech faces a slump with the FDA putting a clinical hold on its Malaria vaccine trial.
BIONTECH News Analytics from Fri, 25 Oct 2024 07:00:00 GMT to Sat, 26 Jul 2025 04:53:09 GMT -
Rating 8
- Innovation 7
- Information 6
- Rumor 6
